Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 08 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Glatiramer Acetate Injection, a generic version of Copaxone, in single-dose prefilled syringes. This approval allows Zydus to provide a cost-effective treatment option for patients with relapsing forms of Multiple Sclerosis. The press release emphasizes Zydus' commitment to developing complex generics and expanding therapeutic choices for patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 08, 2025, titled "Zydus receives final approval from USFDA for Glatiramer Acetate Injection, the generic version of Copaxone? 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases